Pardes Biosciences, Inc. (PRDS)
Pardes Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Carlsbad, CA, US. The stock last traded at $2.18, up 0.93% on the session, giving a market capitalisation of $135.2M. On trailing twelve-month figures it carries a trailing P/E of -1.35, a net margin of 0.0%. Its beta of 0.42 implies it has historically moved less than the broad market.
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.
Pardes Biosciences, Inc. is most often compared with the following Healthcare names: